FDA grants Breakthrough Therapy Designation to the company's drug for a rare, fatal pediatric disorder, paving the way for accelerated review and potential approval.
Shares surged in after-hours trading after the company revealed positive results for its lead drug candidate, Telomir-1, in age-related studies.
Nimacimab monotherapy misses primary weight-loss endpoint, though combination with semaglutide shows promise, raising questions for the drug's future.
The acquisition creates the ninth-largest U.S. bank and signals accelerating consolidation within the regional banking sector.
FDA grants Breakthrough Therapy status for a promising new drug targeting the rare and fatal Sanfilippo Syndrome Type B.
The biotech firm secured its sixth approval for the ZORYVE franchise, expanding its dermatology treatment to children as young as two.
The all-stock deal marks a significant move in the ongoing consolidation wave among U.S. regional banks, creating a new top-ten lender.
The executive search firm's shares jumped over 19% after agreeing to an all-cash acquisition by an investor group led by Advent International and Corvex.